SG11201503231YA - METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES - Google Patents
METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASESInfo
- Publication number
- SG11201503231YA SG11201503231YA SG11201503231YA SG11201503231YA SG11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA
- Authority
- SG
- Singapore
- Prior art keywords
- aureus
- treating
- methods
- associated diseases
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503231YA true SG11201503231YA (en) | 2015-05-28 |
Family
ID=50685101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503231YA SG11201503231YA (en) | 2012-11-06 | 2013-11-05 | METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES |
| SG10201703677VA SG10201703677VA (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201703677VA SG10201703677VA (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (en) |
| EP (1) | EP2928490B1 (en) |
| JP (2) | JP6506172B2 (en) |
| KR (3) | KR20150092738A (en) |
| CN (2) | CN112316135A (en) |
| AU (2) | AU2013341421A1 (en) |
| BR (1) | BR112015010126B1 (en) |
| CA (1) | CA2890385C (en) |
| ES (1) | ES2912267T3 (en) |
| HK (1) | HK1215173A1 (en) |
| MX (1) | MX367082B (en) |
| RU (1) | RU2661406C2 (en) |
| SG (2) | SG11201503231YA (en) |
| WO (1) | WO2014074470A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038509T2 (en) | 2011-06-10 | 2018-10-29 | Medimmune Ltd | Anti-pseudomonas psl binding molecules and uses thereof |
| JP6182152B2 (en) * | 2011-11-07 | 2017-08-16 | メディミューン，エルエルシー | Combination therapy with anti-Pseudomonas Psl and PcrV binding molecules |
| AU2013341361A1 (en) * | 2012-11-06 | 2015-06-04 | Medimmune, Llc | Antibodies to S. aureus surface determinants |
| CN112316135A (en) * | 2012-11-06 | 2021-02-05 | 米迪缪尼有限公司 | Methods of treating staphylococcus aureus-related diseases |
| TWI719938B (en) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | Treatment of polybacterial infections |
| TW202311284A (en) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | Human antibodies to s. aureus hemolysin a toxin |
| WO2020023644A2 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
| TW202035443A (en) | 2018-10-09 | 2020-10-01 | 美商麥迪紐有限責任公司 | Combinations of anti-staphylococcus aureus antibodies |
| CN112538112B (en) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | Antibodies against alpha-hemolysin and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101466406B (en) * | 2006-06-12 | 2012-06-27 | 葛兰素史密斯克蓝生物品公司 | Use of alpha-toxin for treating and preventing staphylococcus infections |
| WO2009029831A1 (en) | 2007-08-31 | 2009-03-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| WO2011008939A2 (en) * | 2009-07-16 | 2011-01-20 | Medical College Of Georgia Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| SG10201600899PA (en) | 2011-02-08 | 2016-03-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| JP2014507142A (en) * | 2011-02-08 | 2014-03-27 | インテグレイテッド バイオセラピューティクス，インコーポレイテッド | Immunogenic composition comprising alpha hemolysin oligopeptide |
| AU2013341361A1 (en) | 2012-11-06 | 2015-06-04 | Medimmune, Llc | Antibodies to S. aureus surface determinants |
| CN112316135A (en) * | 2012-11-06 | 2021-02-05 | 米迪缪尼有限公司 | Methods of treating staphylococcus aureus-related diseases |
| TWI719938B (en) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | Treatment of polybacterial infections |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/en active Pending
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en active Application Filing
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/en not_active Application Discontinuation
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/en not_active Application Discontinuation
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/en active IP Right Grant
- 2013-11-05 MX MX2015005481A patent/MX367082B/en active IP Right Grant
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/en active Pending
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/en active
- 2013-11-05 ES ES13853844T patent/ES2912267T3/en active Active
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/en active IP Right Grant
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/en active Active
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
-
2016
- 2016-03-18 HK HK16103165.5A patent/HK1215173A1/en unknown
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/en active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (en) | SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-RECEPTOR-RELATED DISEASES | |
| SG11201503231YA (en) | METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES | |
| HK1201438A1 (en) | Treatment of ocular disease | |
| EP2906208A4 (en) | Therapeutic treatment | |
| EP2906295A4 (en) | Methods of treating ocular diseases | |
| GB201506561D0 (en) | Treatment of amblyopia | |
| GB201504002D0 (en) | Treatment of intracellular bacterial infection | |
| EP2623494A4 (en) | Agent for treatment of eye diseases | |
| HK1204452A1 (en) | Treatment for bone diseases | |
| IL234606A0 (en) | Novel methods and composition for treatment of disease | |
| EP2704723A4 (en) | Treatment of polycystic disease | |
| HK1216504A1 (en) | Method for treatment of diseases | |
| AP2014007905A0 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| ZA201308194B (en) | Treatment of mastitis | |
| HK1209674A1 (en) | Heterocyclyl carboxamides for treating viral diseases | |
| IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
| HK1208454A1 (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| GB201204645D0 (en) | Treatment of disease | |
| AU2012900983A0 (en) | Novel antibacterial animal therapy | |
| AU2013905016A0 (en) | Treatment of animal fibres | |
| EP2911662A4 (en) | Method of treatment of disease | |
| GB201221118D0 (en) | Methods of treatment | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201206324D0 (en) | Methods of treatment |